CDK9 and NR2E3

Number of citations of the paper that reports this interaction (PubMedID 17255935)
32

Data Source:
HPRD (in vivo)

		CDK9	NR2E3
Description		cyclin dependent kinase 9	nuclear receptor subfamily 2 group E member 3
Image
GO Annotations	Cellular Component	Cyclin-dependent Protein Kinase Holoenzyme Complex Nuclear Chromatin Nucleus Nucleoplasm Chromosome Transcription Elongation Factor Complex Cyclin/CDK Positive Transcription Elongation Factor Complex Membrane PML Body Cytoplasmic Ribonucleoprotein Granule	Nucleus Nucleoplasm Transcription Factor Complex
	Molecular Function	RNA Polymerase II Proximal Promoter Sequence-specific DNA Binding Transcription Coactivator Binding DNA Binding Chromatin Binding Protein Kinase Activity Protein Serine/threonine Kinase Activity Cyclin-dependent Protein Serine/threonine Kinase Activity Protein Binding ATP Binding Transcription Factor Binding RNA Polymerase II CTD Heptapeptide Repeat Kinase Activity Kinase Activity Protein Kinase Binding Cyclin Binding Transcription Regulatory Region DNA Binding 7SK SnRNA Binding	RNA Polymerase II Regulatory Region Sequence-specific DNA Binding RNA Polymerase II Proximal Promoter Sequence-specific DNA Binding DNA-binding Transcription Activator Activity, RNA Polymerase II-specific DNA-binding Transcription Factor Activity Steroid Hormone Receptor Activity Nuclear Receptor Activity Zinc Ion Binding Sequence-specific DNA Binding
	Biological Process	DNA Repair Regulation Of DNA Repair Transcription By RNA Polymerase II Transcription Initiation From RNA Polymerase II Promoter Transcription Elongation From RNA Polymerase II Promoter Protein Phosphorylation Regulation Of Mitotic Cell Cycle Cell Proliferation Positive Regulation Of Cardiac Muscle Hypertrophy Regulation Of Histone Modification Replication Fork Processing Positive Regulation Of Transcription Elongation From RNA Polymerase II Promoter Positive Regulation Of Histone Phosphorylation Response To Drug SnRNA Transcription By RNA Polymerase II Positive Regulation Of Transcription By RNA Polymerase II Positive Regulation Of Viral Transcription Regulation Of Muscle Cell Differentiation Phosphorylation Of RNA Polymerase II C-terminal Domain Negative Regulation Of Cell Cycle Arrest Cellular Response To Cytokine Stimulus Negative Regulation Of MRNA Polyadenylation Positive Regulation Of MRNA 3'-UTR Binding Positive Regulation Of Histone H2B Ubiquitination	Negative Regulation Of Transcription By RNA Polymerase II Regulation Of Transcription By RNA Polymerase II Transcription By RNA Polymerase II Transcription Initiation From RNA Polymerase II Promoter Signal Transduction Visual Perception Phototransduction Negative Regulation Of Cell Proliferation Cell Differentiation Intracellular Receptor Signaling Pathway Eye Photoreceptor Cell Development Steroid Hormone Mediated Signaling Pathway Positive Regulation Of Rhodopsin Gene Expression Positive Regulation Of Transcription By RNA Polymerase II Anatomical Structure Development Retina Development In Camera-type Eye
Pathways		Formation of RNA Pol II elongation complex Formation of HIV elongation complex in the absence of HIV Tat Formation of HIV-1 elongation complex containing HIV-1 Tat Formation of HIV-1 elongation complex containing HIV-1 Tat Pausing and recovery of Tat-mediated HIV elongation Tat-mediated HIV elongation arrest and recovery Tat-mediated elongation of the HIV-1 transcript HIV elongation arrest and recovery Pausing and recovery of HIV elongation Interactions of Tat with host cellular proteins SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription RNA Polymerase II Pre-transcription Events TP53 Regulates Transcription of DNA Repair Genes RNA polymerase II transcribes snRNA genes RNA polymerase II transcribes snRNA genes RNA Polymerase II Transcription Elongation Estrogen-dependent gene expression
Drugs		Alvocidib
Diseases			Vitreoretinal degeneration, including: Stickler syndrome type I (STL1); Stickler syndrome type II (STL2); Snowflake vitreoretinal degeneration (SVD); Wagner syndrome 1 (WGN1); Knobloch syndrome (KNO); Enhanced S-cone syndrome (ESCS); Autosomal dominant vitreoretinochoroidopathy (ADVIRC) Retinitis pigmentosa (RP)
GWAS		Body mass index ( 26426971)	Macular thickness ( 30535121) Metabolite levels (HVA/MHPG ratio) ( 23319000)
Interacting Genes		57 interacting genes: ACTL6A AFF4 AR BCL10 CASK CCNK CCNT1 CCNT2 CDC34 CDC7 CDK5R1 CDK7 CEBPB CTDP1 CTDSPL CUL1 DHX30 EEF1D FBXO25 GRN GTF2F1 H2BC21 HEXIM1 HEXIM2 HLTF HSPA1A HTATSF1 IL6ST MBP MDFIC MED21 MYBL2 MYC NBN NFKB1 NR2E3 PIN1 POLR2A RB1 RCHY1 RELA RMND5B RN7SK SERPINH1 SKP1 SKP2 SMAD1 SMAD2 SMAD3 STAT3 STK36 SUPT5H TAF7 TP53 TRAF2 UBE2A ZMYM6	28 interacting genes: BCL11A CDK9 CRX DEDD2 DHX30 ELAVL2 HDAC1 HDAC3 HOXC13 IRF9 MYBBP1A NCOR1 NR1D1 NR3C1 NRL POLR3D PPARG RARA RBBP4 RBBP7 RBFOX2 RBL1 RXRA RXRB SIN3A SNAPC1 TBL3 ZNF232
Entrez ID		1025	10002
HPRD ID		16016	05132
Ensembl ID		ENSG00000136807	ENSG00000278570
Uniprot IDs		A0A024R880 P50750	F1D8Q9 Q9Y5X4
PDB IDs		1PF6 3BLH 3BLQ 3BLR 3LQ5 3MI9 3MIA 3MY1 3TN8 3TNH 3TNI 4BCF 4BCG 4BCH 4BCI 4BCJ 4EC8 4EC9 4IMY 4OGR 4OR5 5L1Z 6CYT 6GZH	4LOG
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?